I disagree. I believe the analysis is a good move. Prior to MA any PR is going to be a hollow move. This analysis is an equally good - arguably better - measure to get NWBO seen by financial people who might usually not have any visibility on an OTC Biotech. I can only speak for myself, but I'm quite sure a good many longs now have connections in mind that they might actually be willing to share such a report with instead of something generated by one of us retail investors.
Nemesis is full of it. If you have begun believing his pack of utterly inconsistent lies the the FUD is working it's slow spell on you.
My personal opinion and from what I have heard is that the company are itching to give us an update and are equally frustrated by this waiting game as we are. Yes it's ****ing excruciating, but there is only one update that matters to begin with and we all know what that is!
Market Data 
Markets 
AI
